Lumizyme® (alglucosidase alfa) 50 mg vials are supplied as a sterile, nonpyrogenic, white to off-white lyophilized cake or powder in single-dose vials. Lumizyme can be ordered directly from Sanofi Genzyme or through one of our distributors.
NDC(Carton of one single-dose vial)
NDC(Carton of ten single-dose vials)
Please note that a patient's insurance coverage may dictate how Lumizyme should be ordered (e.g., directly by the physician, by a treatment center pharmacy), so be sure to understand your patient's benefits.
If you plan to order directly from Sanofi Genzyme, please contact our Customer Operations group well in advance of your patient's first infusion to establish your account. You will be assigned an Account Manager dedicated to making Lumizyme ordering as seamless as possible.
To get Lumizyme pricing information, set up your account, or place an order, contact Sanofi Genzyme Customer Operations at
, option 1.
Our Account Managers are available Monday through Friday, 8AM to 6PM EST. An after-hours Account Manager is also on call through our answering service to assist with emergency situations.
Execution of a payment agreement is required prior to the purchase of Lumizyme; thereafter, the following terms apply:
Net 60 days, FOB destination, freight pre-paid, effective January 1, 2012
Lumizyme is a non-returnable product, except in cases of Sanofi Genzyme shipping error, product defect, or untreated patient. Sanofi Genzyme reserves the right to review other return requests on a case-by-case basis and may subsequently allow returns at its sole discretion. All returns require prior authorization from Sanofi Genzyme. For return authorization, call your Account Manager at Sanofi Genzyme Customer Operations (, option 1). The Lumizyme Return Goods Authorization Policy is available upon request.
LUMIZYME® (alglucosidase alfa) is a hydrolytic lysosomal glycogen-specific enzyme indicated for patients with Pompe disease (GAA deficiency).
WARNING: RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE
Anaphylaxis and Hypersensitivity Reactions: Life-threatening anaphylaxis and hypersensitivity reactions have been observed in some patients during and after treatment with alglucosidase alfa. If anaphylaxis or severe hypersensitivity reactions occur, immediately discontinue infusion and institute appropriate medical treatment. Appropriate medical support and monitoring measures should be available during infusion.
Immune-Mediated Reactions: Monitor patients for the development of systemic immune-mediated reactions involving skin and other organs. If immune-mediated reactions occur, consider discontinuation of the administration of alglucosidase alfa, and initiate appropriate medical treatment.
Risk of Acute Cardiorespiratory Failure: Patients with acute underlying respiratory illness or compromised cardiac and/or respiratory function may be at risk of serious exacerbation of their cardiac or respiratory compromise during infusions. Appropriate medical support and monitoring measures should be readily available during alglucosidase alfa infusion, and some patients may require prolonged observation times that should be individualized based on the needs of the patient.
Risk of Cardiac Arrhythmia and Sudden Cardiac Death during General Anesthesia for Central Venous Catheter Placement: Administration of general anesthesia can be complicated by the presence of severe cardiac and skeletal (including respiratory) muscle weakness. Therefore, caution should be used when administering general anesthesia. Ventricular arrhythmias and bradycardia, resulting in cardiac arrest or death, or requiring cardiac resuscitation or defibrillation have been observed in infantile-onset Pompe disease patients with cardiac hypertrophy during general anesthesia for central venous catheter placement.
Risk of Antibody Development: Patients with infantile-onset Pompe disease should have a cross-reactive immunologic material (CRIM) assessment early in their disease course and be managed by a clinical specialist knowledgeable in immune tolerance induction in Pompe disease to optimize treatment. CRIM status has been shown to be associated with immunogenicity and patients’ responses to enzyme replacement therapies. There is evidence to suggest that some patients who develop high and sustained IgG antibody titers, including CRIM-negative patients, may experience reduced clinical alglucosidase alfa treatment efficacy.
Monitoring: Laboratory Tests: Patients should be monitored for IgG antibody formation every 3 months for 2 years and then annually thereafter.
The most frequently reported adverse reactions (≥ 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.
Please see the Full Prescribing Information for complete details, including boxed WARNING.